As part of its advisory work for the "Companion Diagnostics" (CDx Platform) reimbursement platform in terms of clinical benefits (diagnostic, prognostic and/or therapeutic) of the molecular tests, ComPerMed has been working on:
- the systematic evaluation of molecular tests used in routine clinical practice in (haemato)-oncology and the genes to be analysed by NGS. A test level is assigned to each biomarker (DNA, RNA, protein). ComPerMed has defined three test levels (see diagram),
- the development of workflows for each type of tumour that show the sequence of molecular tests to be carried out according to good clinical practice.
- the definition of genes that have to be analysed, as a minimum, by NGS for each type of tumour. The choice of these genes is based on the test levels.
Each tumour workflow dispays the sequence of molecular tests that must be carried out to guarantee good clinical practice. Annotations are provided for each test, indicating:
- the test level and
- a brief description.
For each type of tumour, information is provided on its incidence and how this is evolving in Belgium (Cancer Register).
Belgian academic and non-academic experts from several different hospitals assembled to obtain a final workflow that is approved by a large majority.
The workflow are updated on January 15th each year.
Additional updates are possible when requested by experts. A request can be sent by e-mail to the responsibles for updating workflows, Aline Hébrant (Cancer Centre, Sciensano) for solid tumors and Els Van Valckenborgh (Cancer Centre, Sciensano) for haematological cancers.